MarketResearch.biz delivers in-depth insights on the global Ebola vaccine market in its upcoming report titled, “Global Ebola Vaccine Market Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2026”. The global Ebola vaccine market is estimated to register a CAGR of X.X% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2026. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global Ebola vaccine market report has been segmented on the basis of virus strain and region.
Ebola hemorrhagic fever (EHF), also referred as Ebola virus disease causes serious illness, which sometimes results into fatality if untreated. The vaccine that are used to treat Ebola virus disease are referred as Ebola vaccine. After the Ebola virus infection/attack human body shows symptoms – high fever, sore throat, vomiting, diarrhea, muscular pain, and headache. Also, in some cases external or internal bleeding also happens.
Increasing Ebola vaccine research and development around the globe is a major factors driving growth of the global Ebola vaccine market. According to data published by The Lancet – a medical journal, in December 2016, Newlink Genetics and Merck and Company has developed V920 vaccine (rVSV-ZEBOV), which they found effective against Ebola virus disease in phase three clinical trial.
Furthermore, leading players are engaged with product research and development, which is expected to support growth of the target market in next ten years. For example, GlaxoSmithKline plc – a leading player in healthcare market has developed CAd3-ZEBOV vaccine. This vaccine is derived from chimpanzee adenovirus and the phase 3 clinical trials were conducted in February 2016. Also, in 2014, by using recombinant technology Novavax Inc. has developed Ebola vaccine.
The ongoing research activities and under development process drugs are major restraining factors for global Ebola vaccine market. Also, the cases of Ebola virus are recently found on large scale, therefore the research activity has also started recently. According to World Health Organization (WHO), the Ebola virus disease first appeared in 1976, but in 2014–2016 the major outbreak was West Africa, and there were more cases found than combine of all other region.
However, high cost associated research and development of Ebola vaccine is another factor expected to hamper growth of the global Ebola vaccine market up to a certain extent.
North America market dominates the global Ebola vaccine market in terms of revenue contribution as compared to that of markets in other regions. This is mainly attributed to increasing funding for research projects and increasing drug development activity in the region. Europe accounts for second-largest revenue share contribution to the global Ebola vaccine market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively.
Moreover, Asia Pacific region is expected to witness rapid growth over the forecast period. Countries such as India, China are expected to support growth of the market, owing to increasing support for vaccine development program in the region.
Global Ebola vaccine market segmentation, by virus strain:
- Chimpanzee Adeno virus type 3-Zaire Ebola virus
- Recombinant vesicular stomatitis virus-Zaire Ebola virus
- Adeno virus serotype 26- Zaire Ebola Virus
Global Ebola vaccine market segmentation, by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2016 Estimated Year 2017 Forecast Period 2017–2026 Revenue in US$
- Sarepta Therapeutics Inc.
- Mapp Biopharmaceutical Inc.
- Regeneron Pharmaceuticals, Inc.
- Merck & Company, Inc.
- GlaxoSmithKline plc.
- Novavax Inc.
- GeoVax Labs Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!